| Migraine Disorders
Ajovy vs Qulipta
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Ajovy vs Qulipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQulipta has a higher rate of injection site reactions vs Ajovy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qulipta but not Ajovy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ajovy
Qulipta
At A Glance
SC injection
Monthly or every 3 months
CGRP antagonist
Oral
Daily
CGRP receptor antagonist
Indications
- Migraine Disorders
- Episodic migraine
- Migraine Disorders
Dosing
Migraine Disorders 225 mg SC monthly or 675 mg SC quarterly (three consecutive 225 mg injections) into abdomen, thigh, or upper arm.
Episodic migraine Pediatric patients 6 to 17 years weighing 45 kg or more: 225 mg SC monthly.
Migraine Disorders (episodic) 10 mg, 30 mg, or 60 mg taken once daily orally, with or without food.
Migraine Disorders (chronic) 60 mg taken once daily orally, with or without food.
Contraindications
- Serious hypersensitivity to fremanezumab-vfrm or any excipient, including anaphylaxis and angioedema
- History of hypersensitivity to atogepant or any of the components of QULIPTA (reactions have included anaphylaxis and dyspnea)
Adverse Reactions
Most common (>=2%) Injection site reactions (pain, induration, erythema)
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylactic reactions, angioedema, hypertension, Raynaud's phenomenon
Most common (>=4%) Nausea, constipation, fatigue/somnolence
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity (anaphylaxis, dyspnea, rash, pruritus, urticaria, facial edema), hypertension, Raynaud's phenomenon
Pharmacology
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby inhibiting CGRP-mediated signaling implicated in migraine.
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology and is indicated for preventive treatment of migraine in adults.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ajovy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (7/12) · Qty limit (10/12)
Qulipta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Ajovy
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Qulipta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Ajovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Qulipta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QuliptaView full Qulipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.